In response to comments published by Timothy Fernandes et al. to our Letter to the Editor titled “Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19?,”1 we believe it is critical to provide additional information and perspective. Fernandes et al. expressed concern that our survey data of pulmonary arterial hypertension (PAH) and CTEPH patients represented only a snapshot early in the COVID-19 pandemic when the U.S. was at the beginning stages of disease acceleration, and testing was limited. We agree with this observation and have extended our survey window through 6 May 2020, past the peak of COVID activity in much of the U.S. At the end of the survey period, we received a total of 86 responses by PH health care providers, with 66% estimating that their sites had more than 100 PAH and CTEPH patients strengthening our conclusions.